What is Efpeglenatide?
Efpeglenatide is an exendin-based GLP-1 receptor agonist. AMPLITUDE-O examined cardiovascular and kidney outcomes in a high-risk type 2 diabetes population.
Biological role or research focus
Cardiovascular and kidney outcomes in diabetes.
These are findings in people with diabetes and elevated risk, not a longevity trial in healthy adults. Composite endpoints must be read with their component definitions. Sanofi funded the study.
Role reference: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
- Class / identity
- Long-acting exendin-based GLP-1 receptor agonist
- Research focus
- Cardiovascular and kidney outcomes in diabetes
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Source: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
Quick answers
- Is Efpeglenatide FDA approved?
- No. No FDA-approved drug contains Efpeglenatide. Source ↗
- Is Efpeglenatide safe?
- Efpeglenatide is an investigational GLP-1 drug. Large diabetes trials found digestive side effects more often than with placebo; it has no U.S. approval or label. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Efpeglenatide banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| AMPLITUDE-O (2021) | Human randomized trial | 4,076 adults with type 2 diabetes and cardiovascular disease, or kidney disease plus an additional cardiovascular risk factor. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2021
AMPLITUDE-O
Did cardiovascular and renal events differ in high-risk diabetes?
- Population / model
- 4,076 adults with type 2 diabetes and cardiovascular disease, or kidney disease plus an additional cardiovascular risk factor.
- Study design
- Randomized placebo-controlled outcomes trial; median follow-up 1.81 years.
- Main finding
- Major cardiovascular events occurred in 7.0% versus 9.2%: hazard ratio 0.73 (95% CI 0.58–0.92). The renal composite occurred in 13.0% versus 18.4%: hazard ratio 0.68.
- Limits & context
- These are findings in people with diabetes and elevated risk, not a longevity trial in healthy adults. Composite endpoints must be read with their component definitions. Sanofi funded the study.
Source: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
5 registered studies name Efpeglenatide as an intervention; 0 are recruiting or under way, 0 have not started recruiting yet, 1 completed and 4 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise NCT03353350 · Hanmi Pharmaceutical Company Limited | Completed | Phase 3 | 2017-12-05 | 406 |
| Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s) NCT03713684 · Sanofi | Terminated | Phase 3 | 2018-11-09 | 370 |
| Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea NCT03770728 · Sanofi | Terminated | Phase 3 | 2019-08-01 | 312 |
| Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin NCT03684642 · Sanofi | Terminated | Phase 3 | 2018-09-26 | 908 |
| Effect of Efpeglenatide on Cardiovascular Outcomes NCT03496298 · Sanofi | Terminated | Phase 3 | 2018-04-27 | 4076 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. ↗
Cardiovascular diabetology · 2021 Sep 15 · Journal Article, Meta-Analysis, Systematic Review
Read available full text ↗
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. ↗
Journal of the American College of Cardiology · 2025 Nov 18 · Journal Article, Systematic Review, Meta-Analysis
Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis. ↗
Diabetes, obesity & metabolism · 2025 Apr · Comparative Study, Journal Article, Network Meta-Analysis, Systematic Review
Effects of GLP-1 receptor agonists on neurological complications of diabetes. ↗
Reviews in endocrine & metabolic disorders · 2023 Aug · Systematic Review, Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗
Risks & interactions
Efpeglenatide is an investigational GLP-1 drug. Large diabetes trials found digestive side effects more often than with placebo; it has no U.S. approval or label.
Phase 2 and 3 trials, including the AMPLITUDE-O outcomes trial in over 4,000 people with type 2 diabetes, report safety data. Median follow-up was under two years, and results do not apply to unregulated products sold under this name.
Warnings for approved drugs in the same class (semaglutide, tirzepatide, liraglutide, dulaglutide), which may apply here too: Diabetes or blood-sugar medicinesCancer, now or in the pastPregnancy or breastfeedingKidney problemsBlood thinners or bleeding problemsHeart or blood pressure problems
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Side effects reported in studies
- diarrhea
- constipation
- nausea
- vomiting
- bloating
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: AMPLITUDE-O cardiovascular and renal outcomes trial (NEJM, 2021) ↗ · AMPLITUDE-M monotherapy trial (2022) ↗ · Efpeglenatide safety and efficacy meta-analysis (2023) ↗
What the featured evidence can tell us
Diarrhea, constipation, nausea, vomiting, and bloating were more frequent with efpeglenatide. The trial’s favorable event outcomes do not eliminate tolerability problems or establish safety for unrelated preparations.
Source: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
Identity, route, and evidence limits
These are findings in people with diabetes and elevated risk, not a longevity trial in healthy adults. Composite endpoints must be read with their component definitions. Sanofi funded the study.
Source: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. No approval by any regulator was found, but approvals outside the US were not exhaustively checked. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical context & research status
This article summarizes AMPLITUDE-O, not a worldwide approval determination. Regulatory availability and product identity require their own current references.
Source: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. This drug is still investigational and is not approved for sale. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).
How Efpeglenatide works
It stimulates the GLP-1 receptor. The trial connects this receptor-based intervention with clinical events, rather than relying solely on blood-glucose or weight changes.
Source: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
Questions worth asking
- Does a kidney composite prove every kidney outcome improved?
- What population, comparator, and route were actually studied?
- These are findings in people with diabetes and elevated risk, not a longevity trial in healthy adults. Composite endpoints must be read with their component definitions. Sanofi funded the study.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does a kidney composite prove every kidney outcome improved?
No. A composite combines several events. Read the original definitions and individual components before assuming a reduction in dialysis, death, or any particular outcome.
Source: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Source: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
